Compare ELOX & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELOX | INCR |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 58.6M |
| IPO Year | 2013 | 2021 |
| Metric | ELOX | INCR |
|---|---|---|
| Price | $13.20 | $4.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $38.25 | N/A |
| AVG Volume (30 Days) | ★ 17.7K | 3.3K |
| Earning Date | 08-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $203.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.00 | $0.68 |
| 52 Week High | $23.40 | $6.10 |
| Indicator | ELOX | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 41.79 |
| Support Level | $10.74 | $0.81 |
| Resistance Level | $14.65 | $5.58 |
| Average True Range (ATR) | 1.28 | 0.22 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 21.89 | 11.43 |
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.